<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004386</url>
  </required_header>
  <id_info>
    <org_study_id>199/12054</org_study_id>
    <secondary_id>CSH-3660</secondary_id>
    <nct_id>NCT00004386</nct_id>
  </id_info>
  <brief_title>Phase I Pilot Study of Liver-Directed Gene Therapy for Partial Ornithine Transcarbamylase Deficiency</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:

      Evaluate the safety and feasibility of administering recombinant adenovirus containing the
      ornithine transcarbamylase gene to adults with partial ornithine transcarbamylase deficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This a dose escalation study to estimate the maximum tolerated dose of
      recombinant adenovirus encoded with the ornithine transcarbamylase gene.

      Patients receive a single dose of virus infused into the liver under fluoroscopic guidance.
      Groups of 3 patients receive successively higher doses of virus; each cohort is observed for
      safety for 3 weeks before entry of the next group.

      Patients are followed weekly for 1 month, then every 3 months until stable.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 1995</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Ornithine Transcarbamylase Deficiency Disease</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>recombinant adenovirus containing the ornithine transcarbamylase gene</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Confirmed partial ornithine transcarbamylase deficiency
        Asymptomatic, i.e., at least 1 month since hyperammonemia --Prior/Concurrent Therapy-- Not
        specified --Patient Characteristics-- No pregnant or nursing women Negative pregnancy test
        required of fertile women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Batshaw</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Research Institute</affiliation>
  </overall_official>
  <verification_date>January 2000</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>inborn errors of metabolism</keyword>
  <keyword>rare disease</keyword>
  <keyword>urea cycle disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deficiency Diseases</mesh_term>
    <mesh_term>Ornithine Carbamoyltransferase Deficiency Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

